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Coronary heart disease (CHD) mortality rates have decreased in many countries during the last decades.1,2 
Both changes in the rates of out-of-hospital CHD deaths and 
hospitalization rates and the outcome of myocardial infarc-
tion (MI) with ST-segment elevation (STEMI) and non– 
ST-segment elevation (non-STEMI) will affect mortality.3
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It has been suggested that 45% to 75% of the decrease 
in deaths from CHD can be attributed to decreases in smok-
ing, blood pressure, and cholesterol.4–8 These studies based 
their estimates on ecological data or mathematical modeling 
of aggregate data. Few studies used individual person data,9,10 
and the studies were limited to population subgroups and did 
not study out-of-hospital CHD or subtypes of MI.
We used individual person data from repeated surveys of a 
general population to study the rates of out-of-hospital CHD; 
the incidence, treatment, and outcome of hospitalized STEMI 
and non-STEMI; and the impact of changes in coronary risk 
factor levels during the years 1995 to 2010.
Methods
Study Population
The Tromsø Study is a population-based, prospective study of vari-
ous health issues and chronic diseases. It consists of 6 surveys of 
both sexes conducted in the municipality of Tromsø, Norway, from 
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1974 to 2008.11 The present study includes participants from the 
surveys undertaken in 1994 to 1995, 2001 to 2002, and 2007 to 
2008, including a total of 29 582 individuals ≥25 years and older 
who participated in 1, 2, or all 3 surveys. The attendance rates of 
the 1994–1995, 2001–2002, and 2007–2008 surveys were 72%, 79% 
and 66%, respectively. Table I in the online-only Data Supplement 
shows a summary of the surveys. Participants who had previous MI 
(n=734) or had emigrated before the date of examination (n=45) were 
excluded from the analyses. Participants who were still free of MI 
and attended the later surveys in 2001 to 2002 or in 2007 to 2008 had 
their CHD risk factor values updated at the date of their examination. 
The study was approved by the Regional Committee for Medical and 
Health Research Ethics and the Data Inspectorate of Norway. Each 
subject gave written informed consent.
Coronary Risk Factors
Each survey used a standardized almost-identical protocol including 
physical examination, blood sampling, and questionnaires.11,12 Blood 
pressure was measured with an automatic device.12 Nonfasting blood 
samples were analyzed by standard methods at the University Hospital of 
Northern Norway.12 Smoking status was self-reported in a questionnaire. 
Participants were defined as physically active if they performed strenu-
ous physical activity (ie, became sweaty and breathless) at least 1 h/wk.
Identification and Validation of Incident CHD
Incident cases of CHD were recorded from each participant’s study 
entry in 1994 to 1995, 2001 to 2002, or 2007 to 2008 until December 31, 
2010. Adjudication of hospitalized and out-of hospital events was per-
formed by an independent end-point committee using medical records 
and medical notes, autopsy records, and death certificates. The national 
unique 11-digit identification number allowed linkage to national and 
local diagnosis registries. Cases of CHD were identified by linkage to 
the discharge diagnosis registry at the University Hospital of Northern 
Norway, the only hospital in the area, with search for International 
Classification of Diseases, 10th Revision codes I20 to I25, I46, R96, R98, 
and R99. Modified World Health Organization Monitoring Trends and 
Determinants in Cardiovascular Disease (MONICA)/MONICA Risk, 
Genetics, Archiving and Monograph (MORGAM) criteria were used and 
included clinical symptoms and signs, findings in electrocardiograms, 
values of cardiac biomarkers, and autopsy reports when applicable (http://
www.thl.fi/publications/morgam/manual/contents.htm). Biomarkers 
considered were creatine kinase, its myocardial fraction (creatine kinase-
MB), and troponin T beginning in 1999. Biomarker increases associated 
with revascularization procedures were not included as MI. The National 
Causes of Death Registry allowed identification of fatal cases of MI that 
occurred as out-of-hospital deaths and provided information on all-cause 
mortality. Death certificate information was used to collect relevant infor-
mation from additional sources such as autopsy reports and records from 
nursing homes, ambulance services, and general practitioners. We clas-
sified hospitalized STEMI and non-STEMI by using standard criteria.13 
Out-of-hospital sudden death was defined as death caused by a probable 
MI (based on symptoms or autopsy) within 24 hours of symptom onset 
in nonhospitalized individuals or deaths in individuals brought to hospital 
with a cardiac arrest and unsuccessful resuscitation with no evidence of a 
noncoronary cause of death. Case fatality was defined as the proportion 
of incident CHDs that were fatal within 28 days. Dates of emigration 
were obtained from the Population Registry of Norway.
Statistical Analysis
Statistical analyses were performed with STATA 12 (StataCorp LP, 
College Station, TX) and SAS 9.3 (SAS Institute, Cary, NC). Age- and 
sex-adjusted means or prevalence of risk factors over time was esti-
mated from generalized estimating equations to account for depen-
dencies between repeated observations. The identity and logit link 
functions were used for continuous and binary variables, respectively, 
and the estimates were calculated with the use of the mean value for age 
and sex (57.9 years and 46% male) in the regression models. Follow-up 
extended from study entry to the date of incident event, date of emigra-
tion, death, or end of follow-up, whichever came first. Hazard ratios of 
CHD for coronary risk factors were estimated with Cox proportional 
hazards regression adjusted for age and sex. Hazard ratios of subtypes 
of CHD were estimated with the augmented data approach.14 The pro-
portional hazard assumption was verified by Schoenfeld residuals.
For incidence analysis, we used the split function to produce a new 
record for each follow-up year for each person, and age was updated 
every year that the participants were under follow-up. Crude event rates 
were estimated as the number of events per 100 000 person-years. Time 
trends in event and mortality rates and case fatality proportions were 
age and sex standardized with the Tromsø population in 2007 used as 
the standard population for the first 2 end points and the CHD event 
cohort for the last end point. We used a symmetrical moving average 
with a span of 5. This means that we calculated the average of the first 
2 lagged values, the current value, and the first 2 forward terms of the 
series, with each term in the average receiving a weight of 1. The CHD 
mortality decline explained by out-of-hospital sudden deaths was esti-
mated as the difference in out-of-hospital sudden death rate between 
2010 and 1995 divided by the difference in total CHD mortality rate 
between 2010 and 1995. The proportion of the CHD mortality decline 
that was explained by the decline in incidence rates or case fatality was 
calculated as in the MONICA study: The average annual change in 
mortality rate is the sum of the average annual changes in event rate and 
case fatality proportion, expressed as percentages.15 Poisson regression 
models were used to estimate linear time trends in events.
The proportion of the CHD incidence decline that was explained 
by change in each risk factor could be determined in those who par-
ticipated in the 1994–1995 survey and was estimated by the expres-
sion (β0−β1)/β0. We used the same long data set as for the incidence 
analyses described previously. The βs are time-trend coefficients 
from Poisson regression models, the former adjusted for age and sex 
and the latter with additional adjustment for risk factors added to the 
model as time-dependent covariates. End of follow-up was defined 
as 2001 for those who did not attend the 2001–2002 survey and as 
2007 for those who did not attend the 2007–2008 survey. Individuals 
who had a CHD event were censored from the analyses at the time 
of their event. One thousand bootstrapped samples were simulated 
(with replacement) to estimate the 95% confidence interval (CI) for 
the explained decline. A 2-sided significance level was used.
Results
We identified 1845 patients (39% women) with an incident CHD 
event between 1995 and 2010, representing a period of 375 064 
person-years (Table 1). Seventy-eight percent of the patients 
(n=1441) were hospitalized. Among those were 523 patients 
(36%) with STEMI, 869 (60%) with non-STEMI, and 49 with 
unclassifiable MI. A total of 236 hospitalized patients (16%) 
died within 28 days. Among the 404 nonhospitalized patients, 
there were 332 out-of-hospital sudden deaths and 341 deaths 
within 28 days after symptom onset. Thus, 58% of all fatal inci-
dent CHD events occurred as an out-of-hospital sudden death.
CHD Mortality
CHD mortality declined from 137 cases per 100 000 person-years 
in 1995 to 65 cases per 100 000 person-years in 2010 (P<0.001); 
out-of-hospital sudden death declined from 89 cases per 100 000 
person-years in 1995 to 42 cases per 100 000 person-years in 
2010 (P<0.001); and mortality rates among hospitalized MI 
patients declined from 50 cases per 100 000 person-years in 1995 
to 28 cases per 100 000 person-years in 2010 (P<0.001; Figure, 
A). Thus, 65% of the decline in CHD mortality was attributable 
to a decrease in the rates of out-of-hospital sudden deaths.
Using Poisson regression models, we found that the age- 
and sex-standardized CHD mortality rate fell by 7.3% annu-
ally (95% CI, 5.6–8.9; P<0.001 for linear trend), the incidence 
of total CHD by 3.0% annually (95% CI, 2.0–4.0; P<0.001 
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for linear trend), and case fatality by 4.0% annually (95% 
CI,  2.2–5.7; P<0.001 for linear trend; Figure, A–C). Thus, 
changes in incidence and case fatality contributed 43% and 
57%, respectively, to the decline in CHD mortality.
Incidence of CHD
The age- and sex-adjusted incidence of hospitalized STEMI 
decreased from 132 cases per 100 000 person-years in 1995 
to 80 cases per 100 000 person-years in 2010 (average annual 
decrease, 4.3%; 95% CI, 2.5–6.1; P value for linear trend 
<0.001; Figure, B). Similarly, there was a 7.6% (95% CI, 
5.5–9.8; P value for linear trend <0.001) annual decline in out-
of-hospital sudden death. In contrast, hospitalizations for non-
STEMI increased from 120 cases per 100 000 person-years in 
1995 to a peak of 203 cases per 100 000 person-years in 2003, 
followed by yearly decreases to 144 cases per 100 000 person-
years in 2010. The increase in hospitalization for non-STEMI in 
the first half of the study period led to increased incidence rates 
for total CHD from 367 cases per 100 000 person-years in 1995 
Table 1. Baseline Distribution of Risk Factors According to Occurrence of CHD During Follow-Up: The Tromsø Study
Characteristic
No CHD
(n=27 737), % (n)
Any CHD*
(n=1845), % (n)
Out-of-Hospital Sudden 
Death†(n=332) ), % (n)
Hospitalized STEMI‡
(n=523), % (n)
Hospitalized Non-STEMI‡
(n=869), % (n) P Value§
Male sex 46 (12 735) 61 (1130) 56 (186) 67 (351) 59 (515) 0.002
Age ≥60 y 17 (4750) 60 (1111) 73 (242) 49 (258) 61 (532) <0.001
Hyperlipidemia‖ 25 (6821) 51 (935) 47 (154) 55 (286) 50 (431) 0.05
Hypertension¶ 31 (8725) 71 (1306) 76 (252) 65 (340) 72 (623) 0.002
Daily smoking 36 (9850) 41 (756) 39 (128) 49 (255) 37 (323) <0.001
Overweight# 47 (12 942) 65 (1205) 60 (199) 67 (349) 67 (584) 0.04
Diabetes mellitus 2 (402) 7 (121) 7 (24) 5 (25) 8 (66) 0.11
Angina pectoris 2 (544) 14 (256) 15 (49) 10 (51) 16 (141) 0.003
High heart rate** 27 (7419) 33 (611) 40 (133) 32 (168) 32 (278) 0.02
Physical activity†† 33 (9018) 20 (370) 15 (50) 23 (120) 21 (177) 0.02
CHD indicates coronary heart disease; and STEMI, ST-segment–elevation myocardial infarction. 
*All baseline characteristics were significantly different among persons who did and did not develop CHD (all P<0.001).
†Nonhospitalized patients who survived 24 hours (n=72) were not included.
‡Patients hospitalized with unknown myocardial infarction subtype (n=49) were not included. 
§P value for overall difference between out-of-hospital sudden death, hospitalized STEMI, and hospitalized non-STEMI.
‖Ratio of total cholesterol to HDL cholesterol >5.
¶Systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg or using blood pressure lowering drugs.
#Body mass index >25 kg/m2.
**Resting heart rate >80 bpm
††Strenuous physical activity ≥1 h/wk.
Table 2. Age-and Sex-Adjusted Hazard Ratios (95% CIs) for CHD by Baseline Risk Factors: The Tromsø Study
Characteristic
Any CHD
(n=1845)
Out-of-Hospital Sudden 
Death* (n=332)
Hospitalized STEMI†
(n=523)
Hospitalized Non-STEMI†
(n=869) P Value‡
Male sex 1.86 (1.70–2.05) 1.50 (1.21–1.86) 2.40 (2.00–2.88) 1.72 (1.50–1.97) 0.002
Age ≥60 y 7.60 (6.92–8.34) 12.95 (10.21–16.55) 4.75 (4.01–5.65) 8.11 (7.07–9.29) <0.001
Hyperlipidemia§ 2.01 (1.84–2.21) 1.66 (1.33–2.06) 2.41 (2.02–2.86) 1.94 (1.70–2.22) 0.02
Hypertension‖ 1.82 (1.63–2.03) 1.75 (1.33–2.29) 1.70 (1.39–2.07) 1.92 (1.63–2.25) 0.63
Daily smoking 1.80 (1.64–2.00) 1.87 (1.49–2.35) 2.23 (1.87–2.65) 1.54 (1.34–1.77) 0.005
Overweight¶ 1.43 (1.30–1.58) 1.10 (0.88–1.37) 1.58 (1.32–1.90) 1.55 (1.34–1.78) 0.02
Diabetes mellitus 2.44 (2.02–2.94) 2.18 (1.43–3.32) 1.88 (1.25–2.81) 2.86 (2.21–3.68) 0.19
Angina pectoris 2.19 (1.90–2.51) 1.78 (1.30–2.44) 1.73 (1.28–2.33) 2.74 (2.27–3.31) 0.01
High heart rate# 1.30 (1.18–1.43) 1.73 (1.39–2.16) 1.26 (1.05–1.52) 1.25 (1.08–1.44) 0.03
Physical activity** 0.84 (0.74–0.94) 0.73 (0.53–0.99) 0.88 (0.71–1.08) 0.85 (0.72–1.01) 0.60
CHD, coronary heart disease; CI, confidence interval; and STEMI, ST-segment–elevation myocardial infarction. 
*Nonhospitalized patients who survived 24 hours (n=72) were not included. 
†Patients hospitalized with unknown myocardial infarction subtype (n=49) were not included. 
‡P value for overall difference between out-of-hospital sudden death, hospitalized STEMI, and hospitalized non-STEMI. All hazard ratios were adjusted for sex and 
age, except for male sex and age >60 years, which were not adjusted. 
§Ratio of total cholesterol to high-density lipoprotein cholesterol >5. 
‖Systolic blood pressure >140 mm Hg, diastolic blood pressure >90 mm Hg, or use of blood pressure–lowering drugs.
¶Body mass index >25 kg/m2. 
# Resting heart rate >80 bpm. 
**Strenuous physical activity ≥ 1 h/wk.
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to a peak of 431 cases per 100 000 in 2000, then decreasing each 
year to 280 cases per 100 000 in 2010 (Figure, B).
Pre-Event Coronary Risk Factor Levels and 
Manifestations of CHD
Coronary risk factors were associated differently with out-of-
hospital sudden death, hospitalized STEMI, and hospitalized 
non-STEMI (Table 2). Participants with sudden death were 
older, had higher resting heart rates, and were less likely to be 
physically active than those with STEMI or non-STEMI. Male 
sex, hyperlipidemia, and smoking were more strongly associ-
ated with STEMI than with non-STEMI and sudden death. 
Overweight was associated with increased risk of STEMI and 
non-STEMI but not with sudden death. Angina pectoris was a 
stronger risk factor for non-STEMI than for STEMI.
Changes in Coronary Risk Factors and the Decline 
in CHD
Major coronary risk factors changed favorably during the 
study period (Table 3). Mean levels of cholesterol, blood 
pressure, resting heart rate, and smoking were reduced, and 
physical activity was increased. In contrast, overweight and 
diabetes mellitus increased.
The proportion of the decline in the incidence of CHD 
that was attributable to changes in risk factors is presented in 
Table 4. The largest single contribution was declining choles-
terol, which accounted for 32% of the observed 51% decline 
in incident CHD between 1995 and 2010. Changes in sys-
tolic blood pressure, smoking, resting heart rate, and physical 
activity each accounted for 9% to 14% of the decline in risk of 
CHD. Increases in body mass index and the prevalence of dia-
betes mellitus were associated with 7% and 2% increase in the 
risk of CHD, respectively. All risk factors together accounted 
for 66% of the decline in the incidence of CHD (Table 4): 64% 
in women and 61% in men (Tables II and III in the online-only 
Data Supplement).
Characteristics and Treatments of Hospitalized 
Patients
Peak creatine kinase levels was stable over time in patients with 
STEMI but decreased significantly in patients with non-STEMI, 
indicating that non-STEMIs became smaller in the latter part 
of the period (Table 5). The proportion of patients who devel-
oped Q waves on ECG decreased significantly over time among 
patients with both STEMI and non-STEMI. Revascularization 
and the proportion of patients receiving β-blockers, acetylsali-
cylic acid, and statins at discharge increased over time. Age- and 
sex-adjusted 28-day case fatality decreased by 26% (P=0.38) in 
STEMI patients and by 43% (P=0.01) in non-STEMI patients 
in 2005 to 2010 compared with 1995 to 1999.
Discussion
We found a substantial decline in CHD mortality between 1995 
and 2010 that was driven by significant reductions in the inci-
dence of out-of-hospital sudden death and STEMI. Changes in 
cardiovascular risk factors accounted for 66% of the change in 
hospitalized and nonhospitalized fatal and nonfatal CHD, with 
an upper CI close to 100%. This study thus extends results of 
previous studies that found modifiable risk factors to account 
for most cases of hospitalized, nonfatal MI.16
Table 3. Cardiovascular Risk Factor Levels in 1994 to 1995, 2001 to 2002, and 2007 to 2008: The Tromsø Study
Risk Factor
1994–1995
(n=15 718)
2001–2002
(n=6436)
2007–2008
(n=9569)
Relative Change  
From 1994–2008, % P Value*
Age, mean (SD), y 54.8 (10.7) 62.9 (10.3) 59.7 (10.6) <0.001
Male sex, % (n) 47 (7452) 42 (2686) 46 (4414) 0.81
Hyperlipidemia† 31 (30–32) 30 (29–31) 18 (17–19) -42 <0.001
Total cholesterol, mmol/L 6.51 (6.49–6.53) 6.11 (6.09–6.14) 5.61 (5.59–5.63) -14 <0.001
HDL cholesterol, mmol/L 1.55 (1.54–1.55) 1.45 (1.44–1.46) 1.52 (1.51–1.53) -2 <0.001
Hypertension‡ 52 (51–53) 47 (46–48) 48 (47–50) -8 <0.001
Systolic blood pressure, mm Hg 141.9 (141.6–142.3) 136.6 (136.2–137.0) 135.5 (135.1–135.9) -5 <0.001
Diastolic blood pressure, mm Hg 82.1 (81.9–82.3) 80.2 (79.9–80.4) 77.7 (77.5–78.0) -5 <0.001
Drug-treated hypertension 8 (7–8) 14 (13–14) 19 (18–20) 138 <0.001
Daily smoking 34 (33–35) 31 (30–32) 22 (21–23) -35 <0.001
Overweight§ 55 (54–56) 63 (62–64) 63 (62–64) 15 <0.001
Diabetes mellitus 2.2 (1.9–2.4) 2.8 (2.5–3.1) 4.0 (3.7–4.4) 82 <0.001
Angina pectoris 3.1 (2.9–3.4) 2.9 (2.6–3.2) 2.2 (1.9–2.5) -29 <0.001
High heart rate ‖ 30 (29–31) 23 (22–24) 11 (10–11) -63 <0.001
Physical activity¶ 22 (21–23) 36 (34–37) 38 (37–39) 73 <0.001
Values (except for age and sex) are age- and sex-adjusted mean or prevalence (%) with 95% confidence interval for the age group of 40 to 79 years. HDL indicates 
high-density lipoprotein.
*Test for linear trend. 
†Total cholesterol/HDL cholesterol ratio >5.
‡Systolic blood pressure >140 mm Hg, diastolic blood pressure >90 mm Hg, or the use of blood pressure–lowering drugs. 
§Body mass index ≥25 kg/m2. 
‖Resting heart rate >80 bpm. 
¶Strenuous physical activity ≥1 h/wk.
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In line with others, we found that changes in the rates of 
out-of-hospital sudden death had a stronger impact on CHD 
mortality trends than changes in mortality of hospitalized 
patients.17 The study demonstrates that primary prevention by 
modification of risk factors by means of a healthy lifestyle or 
medication will influence both incident CHD and case fatality 
Table 4. Decline in the Risk of a First CHD Event and Percentage of Risk Declines Accounted for by 
Risk Factors: The Tromsø Study
Models
Calendar Time β  
Coefficient per Year
Decline in Risk  
per Year, % (95% CI)
Decline in Risk  
per 15 Years, %*
Explained Decline by Risk 
Factors†, % (95% CI)‡
Model 1, age+sex adjusted −0.0475 4.6 (3.3 to 5.9) 50.9 Referent
Model 1+total cholesterol −0.0323 3.2 (1.8 to 4.5) 38.4   31.9 (22.7 to 48.9)
Model 1+HDL cholesterol −0.0473 4.6 (3.3 to 5.9) 50.8    0.4 (−1.2 to 2.7)
Model 1+SBP −0.0408 4.0 (2.7 to 5.3) 45.7 14.2 (9.5 to 20.4)
Model 1+daily smoking −0.0411 4.0 (2.7 to 5.3) 46.1 13.4 (8.8 to 20.3)
Model 1+BMI −0.0508 5.0 (3.6 to 6.3) 53.3      −7.0 (−11.4 to −3.6)
Model 1+diabetes mellitus −0.0486 4.7 (3.4 to 6.0) 51.7    −2.3 (−4.7 to −0.5)
Model 1+resting HR −0.0406 4.0 (2.6 to 5.3) 45.6 14.5 (6.9 to 24.0)
Model 1 + physical activity −0.0431 4.2 (2.9 to 5.5) 47.6   9.2 (5.0 to 14.5)
Model 1 + all risk factors −0.0162 1.6 (0.1 to 3.0) 21.6   66.1 (47.6 to 96.8)
Physical activity refers to strenuous physical activity ≥1 h/wk. BMI indicates body mass index; CHD, coronary heart disease; 
CI, confidence interval; HDL, high-density lipoprotein; HR, resting heart rate; and SBP, systolic blood pressure
*Decline in risk over 15 years=100%×[1−exp(β×15)].
†Percentage of the observed decline in risk explained by the risk factors=100%×(β0−β1)/β0, where β0 is the coefficient for 
calendar time in the model with adjustment for age and sex only (model 1) and β1 is the coefficient for calendar time in the model 
with additional adjustment for the risk factor(s). 
‡The 95% CI are estimated with 1000 bootstrapped samples. 
Table 5. Characteristics, Treatments, and Case Fatality for Patients Hospitalized With MI in 1995 to 1999, 2000 to 2004, and 2005 to 
2010: The Tromsø Study
1995–1999 2000–2004 2005–2010 P Value*
Patients hospitalized with STEMI
  Patients, n 190 162 171
  Age, mean (SD), y 67.5 (12.2) 66.1 (12.8) 66.5 (11.9) 0.46
  Male sex, % (n) 68 (130) 62 (101) 70 (120) 0.93
  Q-wave in ECG at discharge, % (n) 81 (103) 65 (104) 58 (95) <0.001
  Peak creatine kinase, median (IQR), U/L 1489 (661–3327) 1403 (601–2896) 1411 (551–2540) 0.09
  Revascularization within 28 days, % (n) 14 (26) 64 (103) 87 (149) <0.001
  β-Blockers at discharge, % (n) 79 (90) 94 (129) 89 (116) 0.038
  Acetylsalicylic acid at discharge, % (n) 79 (90) 97 (134) 97 (127) <0.001
  Statins at discharge, % (n) 57 (64) 83 (114) 95 (124) <0.001
  Case fatality within 28 d, % (n) 15 (29) 16 (26) 11 (18)
   Relative risk 1 (Referent) 1.11 (0.66–1.90) 0.74 (0.42–1.35) 0.38
Patients hospitalized with non-STEMI
  Patients, n 216 300 353
  Age, mean (SD), y 69.3 (12.5) 71.2 (13.0) 72.7 (13.1) 0.006
  Male sex, % (n) 64 (139) 56 (169) 59 (207) 0.86
  Q-wave in ECG at discharge, % (n) 37 (61) 14 (40) 13 (45) <0.001
  Peak creatine kinase, median (IQR), U/L 762 (432–1431) 404 (187–961) 326 (130–876) <0.001
  Revascularization within 28 days, % (n) 15 (32) 48 (145) 55 (195) <0.001
  β-Blockers at discharge, % (n) 80 (117) 78 (198) 84 (223) 0.02
  Acetylsalicylic acid at discharge, % (n) 81 (120) 86 (217) 86 (227) 0.035
  Statins at discharge, % (n) 48 (69) 58 (114) 73 (192) <0.001
  Case fatality within 28 d, % (n) 19 (42) 12 (37) 14 (50)
   Relative risk 1 (Referent) 0.55 (0.36–0.86) 0.57 (0.38–0.86) 0.01
IOR indicates interquartile range; MI, myocardial infarction; and STEMI, ST-segment elevation myocardial infarction.
*Age- and sex-adjusted P values for linear trend.
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in populations, shown by the association between coronary 
risk factors and out-of-hospital sudden deaths. Thus, sudden 
death is a preventable condition.18,19
We found that cardiovascular risk factors had different impacts 
on subtypes of CHD, suggesting that the spectrum of CHD mani-
festations among populations and over time may differ, depending 
on the relative prevalence of the risk factors. Our findings sug-
gest that reduced prevalences of hypercholesterolemia and smok-
ing are major driving forces for the decline in the incidence of 
STEMI, indicating that primary prevention efforts result in fewer 
severe events.20,21 In line with this, others have found that cho-
lesterol is associated with rupture of vulnerable plaques and that 
smoking is associated with coronary thrombosis.19
Higher resting heart rate was more strongly associated 
with out-of-hospital sudden death than with STEMI or non-
STEMI (Table 2). Higher heart rates are associated with 
myocardial ischemia, ventricular arrhythmias, and coronary 
atherosclerosis.22–24 Correspondingly, we found that physical 
activity, which lowers resting heart rate, was associated with 
a lower risk of out-of-hospital sudden death and accounted 
for 9% of the decline in total CHD. The prevalence of self-
reported angina pectoris fell by 29% (Table 3), suggesting that 
risk factor changes led to the less coronary atherosclerosis.
As observed earlier, we found an increasing incidence of 
non-STEMI in the first part of the study period,21,25,26 likely 
reflecting the use of more sensitive biomarkers that detect 
smaller myocardial necrosis. This is supported by declin-
ing peak creatine kinase levels among non-STEMI patients, 
whereas the levels were stable in STEMI patients. We believe 
that the decline in STEMI is real and that the initial changes in 
non-STEMI reflect increased diagnostic sensitivity.
A strength of our study is that we used data on an indi-
vidual level from a population-based study with a high atten-
dance rate and standardized survey methods. In addition, case 
finding followed a standardized protocol for ascertainment of 
out-of-hospital and hospitalized events. The inclusion of inci-
dent cases only reduces the possibility that previous cardiovas-
cular disease might have affected the risk factor levels. Finally, 
loss to follow-up is negligible because hospital treatment in 
Norway is free of charge and because of the use of the unique 
personal identity number to search official health registries.
Our study has limitations. We have included a largely 
homogeneous population from Norway that is distinct from the 
US population in which the rate of physical activity is lower, 
the rate of obesity is greater, and the smoking rate is lower. The 
autopsy rate for individuals with out-of-hospital deaths in our 
study was low (9%). This can lead to misclassifications even if 
the predominant cause of sudden death is CHD.18,27,28 In addi-
tion, the true effect of changes in diagnostic sensitivity of bio-
markers could not be fully quantified. The potential bias from 
this would be an overestimation of the incidence of MI in later 
years. The associations between trends in CHD and risk factors 
were necessarily based on attendees in subsequent surveys and 
not the entire source population, which could have introduced 
response and survival biases. The analysis was based on the 
assumption that the effects of changes in risk factors on CHD 
outcomes occurred within the time between consecutive sur-
veys (≈6 years) or between the last survey and 2010 (≈3 years). 
Figure 1. A, Trends in annual incidence rates of total coronary 
heart disease (CHD) mortality, out-of-hospital sudden death, 
and hospitalized fatal myocardial infarctions (MIs), 1995 to 
2010, the Tromsø Study. The incidence rates are fitted as 5 
years–moving mean. Each bar represents 95% confidence 
intervals. Rates are directly age- and sex-standardized to 
the Tromsø population. B, Trends in annual incidence rates 
of coronary heart disease, 1995 to 2010, the Tromsø Study. 
The incidence rates are fitted as 5 years–moving mean. Each 
bar represents 95% confidence intervals. Rates are directly 
age- and sex-standardized to the Tromsø population. STEMI 
indicates ST-segment–elevation myocardial infarction. C, Trends 
in annual case fatality proportion, 1995 to 2010, the Tromsø 
Study. The case fatality proportions are fitted as 5 years–moving 
mean and directly age- and sex-standardized with the event 
cohort as the standard population. Each bar represents 95% 
confidence intervals.
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This might underestimate the effects of a risk factor change if 
a lag time of >3 to 5 years is present before the benefits of a 
risk factor change are realized. However, substantial benefits 
from smoking cessation, changes in blood lipids, and changes 
in blood pressure have been observed within 1 to 3 years.29,30
Conclusions
The substantial decline in CHD mortality was driven by sig-
nificant reductions in the incidence of out-of-hospital sudden 
death and hospitalized STEMI and by a significant reduction 
in case fatality among hospitalized patients. The decline in 
event rates and the decline in case fatality each explained 50% 
of the decline in CHD mortality. Favorable changes in modifi-
able risk factors accounted for 66% of the decline in fatal and 
nonfatal CHD events in this population.
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CLINICAL PERSPECTIVE
We used individual person data from repeated surveys of a general population to study the incidence and outcome of myo-
cardial infarction (MI). From 1995 to 2010, the age- and sex-adjusted incidence of MI decreased by 3%/y. The decline was 
driven by decreases in both out-of-hospital sudden death probably caused by MI and hospitalized ST-segment–elevation MI. 
In contrast, the incidence of hospitalized non–ST-segment–elevation MI increased in the first part of the study period, prob-
ably reflecting the use of more sensitive biomarkers for myocardial damage. We found a reduction in case fatality among 
hospitalized patients. The decline in event rates and case fatality each explained 50% of the decline in MI mortality. Sixty-six 
percent of the decline in MI incidence could be explained by favorable time trends in coronary risk factors. The population 
mean cholesterol level fell 14% between 1995 and 2008. This accounted for 32% of the decline in MI incidence. These 
results indicate that population-wide changes in risk factor levels have a large potential for reducing the MI incidence in a 
population. This study also found that risk factors had different impacts on subtypes of MI, suggesting that the spectrum of 
MI manifestations among populations and over time may differ, depending on the prevalence of risk factors. The association 
between risk factors and out-of-hospital sudden death indicates that primary prevention by modification of risk factors will 
influence both incident MI and case fatality in populations.
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